N/A
Manufactured by Indoco Remedies Limited
17,545 FDA adverse event reports analyzed
Last updated: 2026-04-14
DORZOLAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Indoco Remedies Limited. The most commonly reported adverse reactions for DORZOLAMIDE include TREATMENT FAILURE, DRUG INEFFECTIVE, OFF LABEL USE, FATIGUE, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DORZOLAMIDE.
Out of 7,420 classified reports for DORZOLAMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 17,545 FDA FAERS reports that mention DORZOLAMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include TREATMENT FAILURE, DRUG INEFFECTIVE, OFF LABEL USE, FATIGUE, HEADACHE, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Indoco Remedies Limited in connection with DORZOLAMIDE. Always verify the specific product and NDC with your pharmacist.